NFX Nuformix plc

LSE · GB · Healthcare · Biotechnology · nuformix.com

0.1350GBp-0.37%Mkt Cap: 3.83M $P/E: —Today

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The compan…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap3.83M USD

Enterprise Value2.83M USD

Revenue (TTM)—

Gross Profit0 USD

Net Income (TTM)-709.33K USD

Revenue/Share—

Last Price0.1350 GBp

Fiscal Year EndSep 2025

MR QuarterMar 2026

Employees3

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-4.33

EV/Revenue—

P/S—

P/B1.35

EPS (TTM)0.00

EPS (Forward)—

52W Range

0.12003% of range0.5550

52W High0.5550 GBp

52W Low0.1200 GBp

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-86.44%

ROA-64.05%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-668.05K USD

CapEx (TTM)—

FCF Margin—

FCF Yield-11.08%

Net Debt-1.01M USD

Net Debt/EBITDA1.55

Balance Sheet

Debt/Equity—

Current Ratio4.32

Quick Ratio4.32

Book Value/Sh0.0010 GBp

Cash/Share0.00 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.2.61B

Float2.50B

Insiders5.37%

Institutions0.07%

Technical

SMA 500.1521 (-11.2%)

SMA 2000.1935 (-30.2%)

Beta1.53

S&P 52W Chg14.58%

Avg Vol (30d)29.86M

Avg Vol (10d)21.79M

Technical Indicators

RSI (14)39.8

MACD-0.0051

MACD Signal-0.0041

MACD Hist.-0.0010

BB Upper0.1727 GBp

BB Middle0.1500 GBp

BB Lower0.1273 GBp

BB Width30.33%

ATR (14)0.0145 GBp

Vol Ratio (20d)0.43x